Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 201–300 of 1,003
Update on guidelines for the treatment of chronic musculoskeletal pain
Schnitzer, T. J. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0203-8 · Cited by 161
“In 2004, a large-scale randomised controlled trial of rofecoxib as a prophylactic agent in patients with a history of colorectal adenoma, the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial, revealed a doubling of cardiovascular risk in patients who received rofecoxib for more than 18 months (compared with place…”
BackgroundResultNussmeier, N. A., Whelton, A. A., Brown, M. T., Joshi, G. P., Langford, R. M., Singla, N. K., Boye, M. E., & Verburg, K. M. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00020 · Cited by 162
Mechanisms of Disease: inflammatory mediators and cancer prevention
Mann, J. R., Backlund, M. G., & DuBois, R. N. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0140 · Cited by 167
Cancer chemoprevention: scientific promise, clinical uncertainty
Sporn, M. B., & Liby, K. T. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0319 · Cited by 176
Peutz-Jeghers syndrome: clinicopathology and molecular alterations
McGarrity, T. J., & Amos, C. I. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6080-0 · Cited by 154
Colon cancer: preventive agents and the present status of chemoprevention
Half, E., & Arber, N. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802560153 · Cited by 154
Hudson, M., Richard, H., & Pilote, L. (2005) · BMJ · doi:10.1136/bmj.330.7504.1370 · Cited by 153
Establishing risk of human experimentation with drugs: lessons from TGN1412
Kenter, M., & Cohen, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69562-7 · Cited by 153
Prostacyclin: An Inflammatory Paradox
Stitham, J., Midgett, C. R., Martin, K. A., & Hwa, J. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00024 · Cited by 170
“May 2011 | Volume 2 | Article 24 | 4 predisposed patients (Fitzgerald, 2004; White et al., 2004; Bresalier et al., 2005).”
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications
Lai, K., Chu, K., Hui, W., Wong, B. C., Hu, W., Wong, W., Chan, A. O., Wong, J., & Lam, S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.031 · Cited by 153
Lichtenberger, L. M., Zhou, Y., Dial, E. J., & Raphael, R. M. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.10.0001 · Cited by 168
“…et al 2005) and also to reports that they cause adverse effects to the cardiovascular system, which resulted in the withdrawal of both Vioxx and valdecoxib (Bextra) from the US market as recommended by the FDA (Mukherjee et al 2001; Bresalier et al 2005; Nussmeier et al 2005; Soloman et al 2005).”
BackgroundCurrent and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
“This drug, however, was withdrawn from the market after a study showed an increased cardiovascular risk after long-term use [16].”
BackgroundProstaglandin E2 EP receptors as therapeutic targets in breast cancer
Reader, J. C., Holt, D. M., & Fulton, A. M. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9303-2 · Cited by 170
“Despite inconsistencies in the results of the epidemiological studies, there is evidence that COXibs could reduce the incidence of both familial and sporadic malignant disease, indicating that COX and prostaglandin signaling is a viable target; however, some clinical trials identified increased cardiovascular risk ass…”
ResultAn Overview of Hip Injuries in Running
Paluska, S. A. (2005) · Sports Medicine · doi:10.2165/00007256-200535110-00005 · Cited by 176
Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Lippman, S. M., & Hawk, E. T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1750 · Cited by 165
Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis
Gunter, B., Butler, K. A., Wallace, R. L., Smith, S. M., & Harirforoosh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12484 · Cited by 150
Molecular targets for cancer chemoprevention
William, W. N., Heymach, J. V., Kim, E. S., & Lippman, S. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2663 · Cited by 157
Varas‐Lorenzo, C., Riera‐Guardia, N., Calingaert, B., Castellsague, J., Salvo, F., Nicotra, F., Sturkenboom, M., & Perez‐Gutthann, S. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3437 · Cited by 140
Foodstuffs for Preventing Cancer: The Preclinical and Clinical Development of Berries
Stoner, G. D. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0226 · Cited by 147
Puljak, L., Marin, A., Vrdoljak, D., Markotic, F., Utrobicic, A., & Tugwell, P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009865.pub2 · Cited by 138
COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense
Graham, D. J. (2006) · JAMA · doi:10.1001/jama.296.13.jed60058 · Cited by 161
“Likewise, with APPROVe, an improperly performed and misleading post hoc analysis enabled the company to claim that cardiovascular risk began only after 18 months of continuous rofecoxib use.(10,11) Important considerations for which skepticism was not expressed were that the post hoc analysis should have been only hyp…”
MethodStrand, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61909-6 · Cited by 162
Fosbøl, E. L., Gislason, G. H., Jacobsen, S., Abildstrom, S. Z., Hansen, M. L., Schramm, T. K., Folke, F., Sørensen, R., Rasmussen, J. N., Køber, L., et al. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1592 · Cited by 144
“P rofecoxib and celecoxib, respectively).(2) However, results from the APPROVe study have been questioned and later analyses have demonstrated that the cardiovascular risk was present already after 3–6 months.”
BackgroundResultMechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis
Cronstein, B. N., & Sunkureddi, P. R. (2013) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31827d8790 · Cited by 160
Ray, W. A., Varas-Lorenzo, C., Chung, C. P., Castellsague, J., Murray, K. T., Stein, C. M., Daugherty, J. R., Arbogast, P. G., & García-Rodríguez, L. A. (2009) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.805689 · Cited by 145
Maroon, J. C., & Bost, J. W. (2006) · Surgical Neurology · doi:10.1016/j.surneu.2005.10.023 · Cited by 171
Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
Langley, R. E., Burdett, S., Tierney, J. F., Cafferty, F., Parmar, M. K. B., & Venning, G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.289 · Cited by 144
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H., West, C., Robbins, J., & Niculescu, L. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 143
Sakamoto, C., Sugano, K., Ota, S., Sakaki, N., Takahashi, S., Yoshida, Y., Tsukui, T., Osawa, H., Sakurai, Y., Yoshino, J., et al. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0171-6 · Cited by 143
“selectively inhibit the enzyme responsible for inflammation (cyclooxygenase-2 or Cox-2) has been developed and widely marketed, although a new concern about cardiovascular side effects has emerged with these drugs [4, 11, 34, 41, 48].”
An Evidence-Based Review of the Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs
Farkouh, M. E., & Greenberg, B. P. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.01.014 · Cited by 149
Thromboxane and the thromboxane receptor in cardiovascular disease
Smyth, E. M. (2010) · Clinical Lipidology · doi:10.2217/clp.10.11 · Cited by 157
Angiogenesis in atherosclerosis: gathering evidence beyond speculation
Moulton, K. S. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000245261.71129.f0 · Cited by 156
Progress in COX-2 Inhibitors: A Journey So Far
Chakraborti, A. K., Garg, S., Kumar, R., Motiwala, H. F., & Jadhavar, P. S. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790979980 · Cited by 153
“Various studies suggest that the cardiovascular toxicity associated with the use of selective COX-2 inhibitors might be dependent on the dose as well as on the duration of treatment [13-16].”
BackgroundTherapies targeting lipid peroxidation in traumatic brain injury
Anthonymuthu, T. S., Kenny, E. M., & Bayır, H. (2016) · Brain Research · doi:10.1016/j.brainres.2016.02.006 · Cited by 137
“…930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 increase in ischemic cerebrovascular events (Bresalier et al., 2005).”
Kellogg, A. P., Wiggin, T. D., Larkin, D. D., Hayes, J. M., Stevens, M. J., & Pop-Busui, R. (2007) · Diabetes · doi:10.2337/db07-0740 · Cited by 141
Clinical Pharmacology and Cardiovascular Safety of Naproxen
Angiolillo, D. J., & Weisman, S. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0200-5 · Cited by 158
Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2
Fries, S., Großer, T., Price, T. S., Lawson, J. A., Kapoor, S. C., DeMarco, S., Pletcher, M. T., Wiltshire, T., & FitzGerald, G. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.002 · Cited by 138
NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase
Kolawole, O. R., & Kashfi, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031432 · Cited by 148
“9% of placebo recipients suffered myocardial infarctions or strokes during the trial [63].”
BackgroundThe Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research
Go, A. S., Magid, D. J., Wells, B., Sung, S. H., Cassidy-Bushrow, A. E., Greenlee, R. T., Langer, R. D., Lieu, T. A., Margolis, K. L., Masoudi, F. A., et al. (2008) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.801654 · Cited by 137
The Wnt/β-Catenin Signaling Pathway as a Target in Drug Discovery
Takahashi-Yanaga, F., & Sasaguri, T. (2007) · Journal of Pharmacological Sciences · doi:10.1254/jphs.cr0070024 · Cited by 133
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Hirsh, J., Guyatt, G. H., Albers, G. W., & Harrington, R. A. (2015) · Cited by 137
Bancos, S., Bernard, M. P., Topham, D. J., & Phipps, R. P. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.03.007 · Cited by 148
“This problem was thought to be circumvented by developing highly selective Cox-2 inhibitors (celecoxib, rofecoxib, valdecoxib), however, their use was associated with an increased incidence of myocardial infarction and stroke [12,13].”
BackgroundProstaglandins and sickness behavior: Old story, new insights
Pecchi, E., Dallaporta, M., Jean, A., Thirion, S., & Troadec, J.-D. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.02.040 · Cited by 135
COX-2 Inhibitors and Cardiovascular Risk
Cannon, C. P., & Cannon, P. (2012) · Science · doi:10.1126/science.1224398 · Cited by 144
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer
Karpisheh, V., Nikkhoo, A., Hojjat‐Farsangi, M., Namdar, A., Azizi, G., Ghalamfarsa, G., Sabz, G., Yousefi, M., Yousefi, B., & Jadidi‐Niaragh, F. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106338 · Cited by 140
Diet and Rheumatoid Arthritis: A Review of the Literature
Stamp, L. K., James, M. J., & Cleland, L. G. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.05.001 · Cited by 152
Stark, L. A., Reid, K., Sansom, O. J., Din, F. V., Guichard, S., Mayer, I., Jodrell, D. I., Clarke, A. R., & Dunlop, M. G. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl220 · Cited by 135
ω-3 Polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer
Wang, W., Zhu, J., Lyu, F., Panigrahy, D., Ferrara, K. W., Hammock, B. D., & Zhang, G. (2014) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2014.07.002 · Cited by 135
Colon cancer, fatty acids and anti-inflammatory compounds
Chapkin, R. S., McMurray, D. N., & Lupton, J. R. (2006) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32801145d7 · Cited by 146
Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer
Kerr, D. J., Dunn, J., Langman, M. J. S., Smith, J. L., Midgley, R. S., Stanley, A., Stokes, J. C., Julier, P., Iveson, C., Duvvuri, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071841 · Cited by 133
Chan, C. C., Reid, C. M., Aw, T., Liew, D., Haas, S. J., & Krum, H. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283310dc9 · Cited by 146
Kroon, F. P. B., van der Burg, L. R. A., Ramiro, S., Landewé, R., Buchbinder, R., Falzon, L., & van der Heijde, D. M. F. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010952.pub2 · Cited by 159
Cancer chemoprevention: A radical perspective
Hail, N., Cortes, M., Drake, E. N., & Spallholz, J. E. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.04.004 · Cited by 144
Ruschitzka, F., Borer, J. S., Krum, H., Flammer, A. J., Yeomans, N. D., Libby, P., Lüscher, T. F., Solomon, D. H., Husni, M. E., Graham, D. Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx508 · Cited by 130
Shekhar, S., Cunningham, M., Pabbidi, M. R., Wang, S., Booz, G. W., & Fan, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.028 · Cited by 137
Targownik, L. E., Metge, C. J., Leung, S., & Chateau, D. G. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.010 · Cited by 130
Turajane, T., Labpiboonpong, V., & Maungsiri, S. (2007) · PubMed · Cited by 128
Pyrko, P., Kardosh, A., Liu, Y.-T., Soriano, N., Xiong, W., Chow, R. H.-P., Uddin, J., Petasis, N. A., Mircheff, A. K., Farley, R. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0629 · Cited by 138
Cardiovascular Effects of the Cyclooxygenase Inhibitors
White, W. B. (2007) · Hypertension · doi:10.1161/01.hyp.0000258106.74139.25 · Cited by 128
Selective COX-2 Inhibitors and Risk of Myocardial Infarction
Krötz, F., Schiele, T. M., Klauß, V., & Sohn, H. (2005) · Journal of Vascular Research · doi:10.1159/000086459 · Cited by 128
Ondrey, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0326 · Cited by 126
Different Chemical Structures and Physiological/Pathological Roles of Cyclooxygenases
Faki, Y., & Er, A. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10426 · Cited by 142
Pain Relief in Laparoscopic Cholecystectomy—A Review of the Current Options
Mitra, S., Khandelwal, P., Roberts, K. E., Kumar, S., & Vadivelu, N. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2011.00513.x · Cited by 125
Smith, F. M., Reynolds, J. V., Miller, N., Stephens, R. B., & Kennedy, M. J. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.09.010 · Cited by 125
Pharmacologic Management of Temporomandibular Disorders
Hersh, E. V., Balasubramaniam, R., & Pinto, A. (2008) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2007.12.005 · Cited by 147
Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components
Morlion, B. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.534446 · Cited by 136
Inflammatory angiogenesis in atherogenesis—a double-edged sword
Ribatti, D., Levi‐Schaffer, F., & Kovanen, P. T. (2008) · Annals of Medicine · doi:10.1080/07853890802186913 · Cited by 140
COX-2 Selective Inhibitors in the Treatment of Osteoarthritis
Laine, L., White, W. B., Rostom, A., & Hochberg, M. C. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.10.004 · Cited by 141
“Rofecoxib was withdrawn from the global market t the end of September 2004 after a twofold increased isk of CV thrombotic events with rofecoxib 25 mg daily s compared with placebo was identified in a randomized ontrolled trial (20).”
BackgroundBecker, M. C., Wang, T. H., Wisniewski, L., Wolski, K., Libby, P., Lüscher, T. F., Borer, J. S., Mascette, A. M., Husni, M. E., Solomon, D. H., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.12.014 · Cited by 125
Multimodal Analgesia for Total Joint Arthroplasty
Halawi, M. J., Grant, S. A., & Bolognesi, M. P. (2015) · Orthopedics · doi:10.3928/01477447-20150701-61 · Cited by 124
Arehart, E. J., Stitham, J., Asselbergs, F. W., Douville, K. L., MacKenzie, T. A., Fetalvero, K. M., Gleim, S., Kasza, Z., Rao, Y., Martel, L., et al. (2008) · Circulation Research · doi:10.1161/circresaha.107.165936 · Cited by 124
“(3) the cytoplasmic or intracellular domain that is made up of”
BackgroundIncreased Superoxide and Endothelial NO Synthase Uncoupling in Blood Vessels of Bmal1-Knockout Mice
Anea, C. B., Cheng, B., Sharma, S., Kumar, S., Caldwell, R. W., Yao, L., Ali, M. I., Merloiu, A. M., Stepp, D. W., Black, S. M., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.261750 · Cited by 121
Prostanoids in nociception and pain
Zeilhofer, H. U. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.07.037 · Cited by 136
“Later, skepticism reached a maximum when Merck withdrew its rofecoxib (VIOXX) from the market following results from a controlled clinical trial (APPROVe [7]) that suggested that the risk of cardiovascular events was nearly twice as high in patients who had”
BackgroundNonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice
Ho, K. Y., Gwee, K. A., Cheng, Y. K., Yoon, K. H., Hee, H. T., & Omar, A. R. (2018) · Journal of Pain Research · doi:10.2147/jpr.s168188 · Cited by 110
“008).(34) Results from these studies led to the worldwide withdrawal of rofecoxib in 2004.”
ResultBingham, C. O., Sebba, A. I., Rubin, B. R., RUOFF, G. E., Kremer, J. M., Bird, S., Smugar, S. S., Fitzgerald, B. J., O'Brien, K., & Tershakovec, A. M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel296 · Cited by 123
“The observation, that long-term, unopposed selective COX-2 inhibition may be associated with thrombotic CV and cerebrovascular side effects greater than placebo has raised concerns about the safety and future use of these agents in spite of their efficacy and improved GI tolerability compared with traditional NSAIDs […”
BackgroundThe role of COX-2 and Nrf2/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging
Luo, C., Urgard, E., Vooder, T., & Metspalu, A. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.04.002 · Cited by 131
“Inhibition of COX-1 by aspirin has been proven to reduce cardiovascular risk, whereas selective COX-2 inhibition increases cardiovascular events, such as stroke or myocardial infarction [7,8].”
BackgroundPrimum Non Nocere: An Evolutionary Analysis of Whether Antidepressants Do More Harm than Good
Andrews, P. W., Thomson, J. A., Amstadter, A., & Neale, M. C. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00117 · Cited by 120
“In comparison, rofecoxib (Vioxx) was pulled off the market amidst evidence that it caused about 7.2 cardiovascular events per 1000 patient-years and a lower risk of death (Bresalier et al., 2005).”
BackgroundInfluentialKurmis, A. P., Kurmis, T. P., O’Brien, J. X., & Dalén, T. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.j.01743 · Cited by 132
Heart Failure Induced by Non-Cardiac Drugs
rdal, L. S., & Spigset, O. (2006) · Drug Safety · doi:10.2165/00002018-200629070-00003 · Cited by 124
N??sdal, J., & Brown, K. A. (2006) · Drug Safety · doi:10.2165/00002018-200629020-00002 · Cited by 139
“3 Dose of NSAID with placebo.[70,71] Furthermore, parecoxib and valdecoxib increased the risk of cardiovascular In the meta-analysis by Henry et al.”
BackgroundManaging the adverse effects of nonsteroidal anti-inflammatory drugs
Patrignani, P., Tacconelli, S., Bruno, A., Sostres, C., & Lanas, A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.36 · Cited by 119
Farkouh, M. E., Greenberg, J., Jeger, R. V., Ramanathan, K., Verheugt, F. W. A., Chesebro, J. H., Kirshner, H. S., Hochman, J. S., Lay, C. L., Ruland, S. D., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066001 · Cited by 119
Strillacci, A., Valerii, M. C., Sansone, P., Caggiano, C., Sgromo, A., Vittori, L., Fiorentino, M., Poggioli, G., Rizzello, F., Campieri, M., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4097 · Cited by 118
“3 myocardial infarction in chronically treated patients [6].”
BackgroundCyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery
Holte, K., Andersen, J., Jakobsen, D. H., & Kehlet, H. (2009) · British journal of surgery · doi:10.1002/bjs.6598 · Cited by 118
Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids
Rouzer, C. A., & Marnett, L. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800005200 · Cited by 117
Advances in eicosanoid research, novel therapeutic implications
Haeggström, J. Z., Rinaldo-Matthis, A., Wheelock, C. E., & Wetterholm, A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.140 · Cited by 118
Cortes-Ciriano, I., Murrell, D. S., van Westen, G. J., Bender, A., & Malliavin, T. E. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-014-0049-z · Cited by 118
Precision Prevention and Early Detection of Cancer: Fundamental Principles
Rebbeck, T. R., White, K. B., Chan, A. T., Emmons, K. M., Freedman, M. L., Hunter, D. J., Kraft, P. L., Laden, F., Mucci, L. A., Parmigiani, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1415 · Cited by 126
“For example, experience with COX2 inhibitor chemoprevention among individuals at high risk for colorectal cancer that led to elevated cardiovascular risk is a cautionary tale of unintended effects of a prevention intervention (43).”
BackgroundCardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function
Wang, D., Patel, V. V., Ricciotti, E., Zhou, R., Levin, M. D., Gao, E., Yu, Z., Ferrari, V. A., Lu, M. M., Xu, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805806106 · Cited by 116
Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines
Lev‐Ari, S., Vexler, A. M., Starr, A., Ashkenazy‐Voghera, M., Greif, J., Aderka, D., & Ben‐Yosef, R. (2007) · Cancer Investigation · doi:10.1080/07357900701359577 · Cited by 117
Pro-inflammatory prostaglandins and progression of colorectal cancer
Wang, D., & DuBois, R. N. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.004 · Cited by 130
“Prolonged use of high doses of NSAIDs (except for aspirin) is associated with unacceptable cardiovascular side effects [58–60].”
BackgroundCOX-2–Derived Prostacyclin Modulates Vascular Remodeling
Rudic, R. D., Brinster, D. R., Cheng, Y., Fries, S., Song, W., Austin, S. C., Coffman, T. M., & FitzGerald, G. A. (2005) · Circulation Research · doi:10.1161/01.res.0000170888.11669.28 · Cited by 116
Schmidt, M., Hallas, J., & Friis, S. (2014) · Clinical Epidemiology · doi:10.2147/clep.s59156 · Cited by 115
“The withdrawal of rofecoxib contributed to the subsequent reduction in use of all coxibs following 2004, including celecoxib.(8) The increased focus on the cardiovascular toxicity associated with nonaspirin NSAID use in general, and COX-2 selective NSAIDs in particular, may also have contributed to the overall decreas…”
InfluentialStamatakis, E., Weiler, R., & Ioannidis, J. P. A. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12074 · Cited by 113
Virdis, A., Bacca, A., Colucci, R., Duranti, E., Fornai, M., Materazzi, G., Ippolito, C., Bernardini, N., Blandizzi, C., Bernini, G. P., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00995 · Cited by 129
“Apparently, at variance with results from this study, previous clinical trials raised concerns about an increased cardiovascular risk associated with the COX-2 inhibitor rofecoxib in patients with rheumatoid arthritis or colorectal adenoma.(27,28) Furthermore, subsequent studies conducted with more selective COX-2 inh…”
ResultCardioprotective prostacyclin signaling in vascular smooth muscle
Fetalvero, K. M., Martin, K. A., & Hwa, J. (2006) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.05.011 · Cited by 116
Non‐steroidal anti‐inflammatory drugs for the prevention and treatment of cancer
Pereg, D., & Lishner, M. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01519.x · Cited by 123
Motsko, S. P., Rascati, K. L., Busti, A. J., Wilson, J. P., Barner, J. C., Lawson, K. A., & Worchel, J. (2006) · Drug Safety · doi:10.2165/00002018-200629070-00007 · Cited by 115
Macrophage EP4 Deficiency Increases Apoptosis and Suppresses Early Atherosclerosis
Babaev, V. R., Chew, J. D., Ding, L., Davis, S., Breyer, M. D., Breyer, R. M., Oates, J. A., Fazio, S., & Linton, M. F. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.005 · Cited by 114
“Selective inhibition of COX-2 and nonselective inhibition of COX by NSAIDs have been reported to increase the risk for cardiovascular events (Bresalier et al., 2005; Grosser et al., 2006; Solomon et al., 2005).”
Pulichino, A.-M., Rowland, S., Wu, T. Y.-H., Clark, P., Xu, D., Mathieu, M., Riendeau, D., & Audoly, L. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110387 · Cited by 131
“There is now emerging evidence that chronic use of COX-2-specific inhibitors and NSAIDs in- crease the risk of cardiovascular side effects (http://www. fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf) (Bresalier et al., 2005).”
Background
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.